Sofinnova Investments’s Prometheus Biosciences, Inc. Common Stock RXDX Stock Holding History

Sofinnova Investments’s Portfolio RXDX Stock Details RXDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-123,842	Closed	-$13.3M	–	67
2023 Q1	$13.3M	Sell	123,842 -52,703	-30%	-$6.07M	0.85%	29
2022 Q4	$19.4M	Buy	176,545 +36,771	+26%	+$2.38M	1.15%	22
2022 Q3	$8.25M	Sell	139,774 -246,621	-64%	-$11.3M	0.48%	35
2022 Q2	$10.9M	Buy	+386,395	New	+$11.2M	0.91%	27

Other funds holding RXDX

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

FCA

FinTrust Capital Advisors Greenville, South Carolina $591M AUM 26.89% 1-Year Est. Return

Sofinnova Investments's RXDX Position: Q2 2023 in Review

Sofinnova Investments sold out of Prometheus Biosciences, Inc. Common Stock (RXDX) in Q2 2023, closing a stake of 123,842 shares — an estimated $13.3M sold.

Sofinnova Investments first reported a position in RXDX in Q2 2022 and held it in 4 quarters. The position peaked at $19.4M in Q4 2022. 2 funds tracked by Wall St. Rank hold RXDX as of Q2 2023.

Sofinnova Investments reported no remaining Prometheus Biosciences, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Sofinnova Investments sold 123,842 Prometheus Biosciences, Inc. Common Stock shares in Q2 2023, an estimated $13.3M.
Sofinnova Investments first reported a position in Prometheus Biosciences, Inc. Common Stock in Q2 2022 and held it in 4 quarters.
Sofinnova Investments's Prometheus Biosciences, Inc. Common Stock position peaked at $19.4M in Q4 2022.
2 funds tracked by Wall St. Rank held Prometheus Biosciences, Inc. Common Stock as of Q2 2023.

Based on Sofinnova Investments's 13F filing for Q2 2023, filed 14 Aug 2023.